

# Index

- abridged life tables, 73–6, 90, 381, 392
- ABS DataLab, 115
- absolute risk difference, 230, 291
  - see also* attributable risk
- accuracy, 297–8
- active surveillance systems, 19
- additive interaction, 295, 296, 297
- adiponectin, 283–4
- adjusted rates, 51
- aetiological study designs, 107–8
  - see also* analytical study designs
- aetiology, 97
  - see also* causation
- age, 124, 225, 294–5, 337–8
- age-dependency, 51, 63
- age-specific rates, 51, 65
- age-standardised rates, 66–72, 81, 225
- age structure, 51, 61–9, 72, 79, 86, 88–90, 225, 341, 380, 382, 385, 392
- ageing of populations, 140, 225
- aggregated data, 114
- alcohol consumption, 170, 303
- allocation bias, 327
- allocation concealment, 255–6, 257–8
- alternative hypotheses, 264, 300
- Alzheimer's disease, 63, 127
- analytical cross-sectional studies, 106, 139, 161, 165–77
  - examples, 22, 167–8, 170, 284
- analytical study designs, 21–2, 106–7, 165
  - see also* aetiological study designs; analytical cross-sectional studies; case-control studies; cohort studies; ecological studies
- annual rates, 49, 50
- antagonism, 295
- antenatal depression, 371
- arthroscopy, 256
- asbestos, 295–7
- ascertainment bias, 325, 326, 328
- association, measures of, *see* measures of association
- Association of the Nordic Cancer Registries (NORDCAN), 149
- associations, 21, 170–7
- asthma, 10, 361
- attributable proportion, 292
- attributable risk, 291–4
  - see also* absolute risk difference
- attrition bias, 232, 233, 237, 238, 327–9, 340, 364, 401
- Australia
  - cancer in, 135–6, 148–9, 224–5, 303, 362
  - Cancer Institute NSW, 201
  - census data in, 140
  - Centre for Disease Control, 151
  - consumer regulation in, 11
  - COVID-19 in, 135, 151
  - Health-Adjusted Life Expectancy in, 84–5
  - health priorities in, 16
  - hepatitis A in, 209
  - hepatitis C in, 305
  - Human Research Ethics Committees, 266
  - Indigenous Australians, 16, 84–5, 125
  - influenza in, 8, 51–4, 124–5, 146
  - life expectancy in, 125
  - limb defects in babies in, 110–11
  - National Health and Medical Research Council, 305
  - National Health Survey, 139, 167, 177, 183
  - National Notifiable Diseases Surveillance System, 144, 145, 146
  - National Statement on Ethical Conduct in Human Research, 266
  - National Suicide and Self-Harm Monitoring System, 149
  - obesity in, 16, 362
  - population surveys in, 125, 139, 167
  - Potential Years of Life Lost in, 79
  - suicide in, 149
  - use of placebos in, 267
  - see also* Queensland; South Australia; Victoria
- Australian Bureau of Statistics (ABS), 52, 115, 139, 140, 177, 349
- Australian Institute of Health and Welfare (AIHW), 79, 84, 135, 139, 149
- Australian New Zealand Clinical Trials Registry, 334
- autism, 305
- babies, 108–12, 167–8
- background rate, 230, 291
- bar charts, 8
  - see also* histograms
- bathtub analogy, 40–3, 59, 391
- beneficence, 106
- bias, 7–8, 322–34
  - assessing potential for, 363–6
  - in case-control studies, 204–9, 327, 328, 331, 333
  - in cohort studies, 230–6, 237–8, 327, 328, 329, 331, 333, 364
  - in randomised controlled trials, 327, 328, 329, 331, 333
  - see also* measurement bias; selection bias
- big data, 4
- biobanks, 193, 203
- biological interaction, 295–7
- blinding, 236, 250, 256–7, 333
- block randomisation, 254
- blood samples, 167
- bone fracture, 287–8
- Boolean operators, 368–9
- Bradford Hill, Sir Austin, 95, 98
  - criteria for causation, 98, 289
- brain cancer, 222
- Brazil, 142–3, 284
- breast cancer, 44, 51, 212, 303, 305, 311, 362, 391, 405
- British Doctors Study, 95–7, 104
- Broad Street Pump study, 15, 115, 130–1
- burden of disease, 38, 86, 140, 144
- burden of disease studies, 38, 112–13, 114
- cancer, 51
  - brain, 222
  - breast, 44, 51, 212, 303, 305, 311, 362, 391, 405
  - diet and, 178
  - leukaemia, 222
  - liver, 362
  - lung, 95–7, 135–6, 292, 295–7, 364–6, 367
  - mesothelioma, 295
  - registries, 148–9, 163, 201, 222, 237
  - reporting of, 224
- Cancer Institute NSW (Australia), 201
- cardiovascular disease, 16, 85, 96, 104, 116, 172, 202, 212, 218, 220, 223, 308
- case-control studies, 22, 98, 107, 114, 191–210, 285, 328, 362
  - bias in, 204–9, 327, 328, 331, 333
  - compared with retrospective cohort studies, 219
  - definition of cases, 199–201
  - and epidemics, 191, 285
  - examples, 22, 108, 109, 194, 204, 286, 362

- case-control studies (cont.)
  - identification of potential exposures, 192–3
  - internal validity, 324
  - and odds ratios, 193–9, 285
  - selection of controls, 201–3
  - strengths and limitations of, 209–10
- case fatality, 42–4, 55–7, 135, 352, 390, 391
- case-fatality rate, 56, 135, 178, 352, 381, 390, 391
- case-fatality risk, 56
- case reports, 21, 114, 129, 137
- case series, 108, 114, 129, 137–8
- cases, definition of, 199–201
- causation, 98–9, 289–91
  - see also* aetiology
- cause-specific mortality, 84
- cause-specific mortality rates, 56
- census data, 139–41, 151
- Centers for Disease Control and Prevention (United States), 145
- Centre for Disease Control (Australia), 151
- chance, 334
- childbirth, 50
- children, 125, 222–3, 260–1
  - see also* babies; young adults
- China, 17, 194, 295, 361
- cholera, 15, 130–1, 286
- cholesterol, 284
- chronic conditions, 37
- chronic obstructive pulmonary disease, 85
- climate change, 183
- clinical significance, 281, 304
- clinical trials, 104, 107, 248, 324–5, 326, 334
  - see also* randomised controlled trials (RCTs)
- cluster sampling, 164
- Cochrane Collaboration, 363–4, 372
- Cochrane Library, 252, 350
- cohort life tables, 74–5, 76
- cohort studies, 21, 98, 107, 114, 218–38, 287, 328, 362
  - bias in, 230–6, 237–8, 328, 329, 333
  - examples, 21, 95–6, 287–8, 362–3
  - internal validity of, 325
  - measuring outcomes in, 224–30
  - problems with reproducibility, 356
  - prospective, *see* prospective cohort studies
  - and relative risk, 287, 289
  - retrospective, *see* retrospective cohort studies
  - strengths and limitations of, 236–8
- colds, 7, 99
  - Rothman's model of causation, 290–1
  - see also* common cold
- common cold, 9, 14, 98–99, 102–4, 106, 114, 394
  - see also* colds
- communicable diseases
  - as causes of death, 127
  - see also* infectious diseases
- Community Intervention Trial for Smoking Cessation (COMMIT) (United States), 104–5
- community interventions (community trials), 23, 104–5, 107, 114
- complete life tables, 73
- computerised tomography (CT), 222–3
- concealment of allocations, 255–6, 257–8
- concurrent studies, *see* prospective cohort studies
- confidence intervals, 197–9, 204, 228, 260, 264, 286, 299, 301, 334, 350, 351, 352, 359, 367
- confounders, 225, 294–5
- confounding, 7–8, 184, 236, 334–41, 366–7
- consent, informed, 268
- CONSORT Statement, 353
- conspiracy theories, 5
- construct validity, 318–19, 320
- consumer regulation, 11
- content validity, 318, 320
- Content Validity Index, 321
- contingency tables (2 x 2 tables), 103, 170, 171
- controls, selection of, 201–3
- convenience sampling, 170
- coronary heart disease, 85, 123
- coronaviruses, 9
- correlation, 178, 282–3
- correlation coefficients, 283
- covariate adaptive randomisation, 255
- COVID-19, 3, 9
  - and alcohol consumption, 170
  - in Australia, 135, 151
  - bathtub analogy, 42–3
  - in children, 260–1
  - in China, 194, 295
  - and diabetes, 229–30, 291–2
  - growth in number of cases, 133
  - identification of earliest cases, 17
  - impact of ethnicity, 204
  - impact on healthcare workers, 221, 350–2, 362
  - impact on life expectancy, 73
  - impact on mental health, 161
  - incident *v.* prevalent cases, 40
  - in India, 191–2
  - International Classification of Diseases codes, 17
  - long, 371
  - long-term observations, 134–5
  - and loss of muscle-mass, 251
  - in Mexico, 251, 260–1, 350–2
  - and multi-organ dysfunction, 223, 227
  - as notifiable disease, 145
  - in older people, 151–2
  - Our World in Data platform, 148
  - personal protective behaviour, 5, 14, 221
  - polymerase chain reaction tests, 23, 37
  - prevention, 14
  - rapid antigen tests, 23, 99
  - and respiratory disease, 228
  - role of epidemiology, 24–5
  - Rothman's model of causation, 291
  - in Saudi Arabia, 251
  - symptoms, 99
  - and thromboembolism, 362–3
  - treatments, 22–3, 251, 260–1, 363
  - in United Kingdom, 204, 221, 223, 227–8, 362–3
  - in United States, 151, 170, 221, 251
  - vaccines, 5–6, 14, 134, 135
  - variants, 134, 135
  - World Health Organization and, 17, 131–2, 145, 148, 150
  - in young adults, 151
  - see also* SARS-CoV-2
- criterion validity, 319, 320
- critical thinking, 4–15
  - absence of, 5–6
  - analysing in, 6–10
  - application to scientific literature of, 349–50, 353
  - compared with uncritical thinking, 372
  - decision-making in, 14
  - evaluating in, 10–12
  - problem-solving in, 13–14
  - reasoning in, 12–13
- cross-sectional studies, 107, 114, 361
  - analytical, *see* analytical cross-sectional studies
  - data requirements, 182–3
  - descriptive, 21, 106
  - establishing associations in, 170–7
  - examples, 21, 361
  - longitudinal, 177
  - strengths and weaknesses of, 169–70
- crossover randomised controlled trials, 250, 267
- crude rates, 51, 64–5
- Danish HIV Cohort Study, 287
- data
  - aggregated, 114
  - big, 4
  - census, 139–41, 151
  - collection of, 48–9
  - de-identified, 8

- linkage of, 150
- micro, 114
- mortality, 16–17, 143–4
- primary, 113–14, 137–9
- secondary, 113, 114, 137, 139–44
- self-reporting of, 330, 331, 332, 333
- standards for, 17
- Declaration of Helsinki, 266
- de-identified data, 8
- dementia, 37, 40, 42, 43, 63, 127, 295
- dengue, 190
- Denmark, 287–8
- depression, 63, 167, 232, 371
- descriptive cross-sectional studies, 21, 106
- descriptive epidemiology, 81, 113, 122–3
  - collection and interpretation of data for, 136–51
  - importance of, 151–2
  - personal characteristics in, 124–9
  - place characteristics in, 129–33
  - purposes of, 152
  - time characteristics in, 133–6
  - see also* burden of disease studies; health problems, identification of
- descriptive study designs, 20–1, 106
  - see also* case reports; case series; cross-sectional studies, descriptive
- determinants of health, social, 24, 125, 165
- diabetes, 16, 37, 40, 42, 167, 339
  - and COVID-19, 229–30, 291–2
  - type 1, 213, 388
  - type 2, 85, 339
- diagnostic studies, 23
- dichotomous scales, 99–100, 103
- dichotomous variables, 100
- diet, 178
- direct marketing, 11
- direct standardisation, 66–70
- directed acyclic graphs (DAGs), 336–7
- Disability-Adjusted Life Years (DALYs), 81–2, 86–7, 113, 142
- Disability-Free Life Expectancy (DFLE), 81
- disease, multicausal nature of, 161–2
- disease prevention levels, 43
- disease surveillance, 4, 18–20, 133, 144–50, 151
  - systems, 19, 144–50, 151
- Doll, Sir Richard, 95
- dose–response relationships, 96, 289
- double-blind randomised controlled trials, 250
- drugs, safety testing of, 112
  - duration, 41, 42, 5, 55, 86, 87
- E*-values, 236
- ecological fallacy, 116, 184
- ecological studies, 22, 107, 114, 115, 161, 177–84, 361
- effect modification, 295
- election polling, 323–4
- electronic health records (EHRs), 149
- epidemic curves, 135
- epidemics, 4, 135, 152, 190, 191, 285
- epidemiological studies, 48, 95
  - see also* study designs
- epidemiological transition, 24–5
- epidemiology, 4, 24–5, 81
  - see also* descriptive epidemiology; epidemiological studies; social epidemiology
- equipoise, 267
- estimated resident population tables, 50
- ethical perspectives, 103–4, 106, 223, 249, 265–8
- Ethiopia, 286
- ethnicity, 204
- Eurostat, 69
- evidence, synthesising of, 369–70
  - see also* systematic reviews
- evidence hierarchy, 246, 247
- experimental study designs, 20, 22–3, 103, 104, 106
  - compared with non-experimental study designs, 104, 106, 247
  - ethical perspectives, 103–4
  - see also* clinical trials; community interventions (community trials)
- exposures, 12, 98, 102–3, 161, 192–3
- external validity, 299, 318, 324
- feel-osophy, 5, 7, 349
- FluNet, 147
- follow-up studies, 177
  - see also* cohort studies; experimental study designs
- food poisoning, 133
- Framingham Heart Study, 104, 220, 232
- France, 363
- frequency counts, 35–44, 61–4
  - see also* incident cases; prevalent cases
- gastrointestinal diseases, 191, 200
  - see also* salmonellosis
- Germany, 108–10, 111
- Global Burden of Disease study, 86, 144, 177, 183
- Global Cancer Observatory, 149
- Global Health Estimates, 141, 142, 150, 151, 184
- Global Health Observatory, 150
- Global Influenza Programme, 147
- Global Influenza Surveillance and Response System (GISRS), 147
- Golden Square, London, 130
- Google Scholar, 349
- graphs, 8
  - see also* directed acyclic graphs (DAGs); Kaplan-Meier curves; scatter plots
- Graunt, John, 16–17, 73
- gross domestic product (GDP) per capita, 178
- handwashing, 5, 14, 234
- Hawthorne effect, 233–4, 331, 332–3
- hazard ratio, 358
- HDL-cholesterol, 284
- Health-Adjusted Life Expectancy (HALE), 81–6
- health expectancy measures, 86
- health gap measures, 86
- health priorities, setting of, 15–17
  - see also* disease surveillance
- health problems, identification of, 122
  - see also* descriptive epidemiology
- health sciences, 4, 6
- healthcare workers
  - handwashing in, 234
  - impact of COVID-19 on, 221, 350–2, 362
- Healthy Life Expectancy (HLE), 81
- healthy worker effect, 205, 232–3, 327, 329
- hepatitis A, 209
- hepatitis C, 288, 305, 339, 362, 371
- hepatocellular carcinoma, 362
- hierarchy of evidence, 246, 247
- high blood pressure, 335
- high-income countries, 127, 178, 237, 250
- highly active antiretroviral therapy (HAART), 287–8
- Hill, Sir Austin Bradford, *see* Bradford Hill, Sir Austin
- Hispanic people, 355–6
- histograms, 135
  - see also* bar charts
- HIV, 251–2, 258–9, 262–3, 287–8, 357–60
- hospital admissions, 124, 149
- hospital records, 149, 167, 193
- Human Research Ethics Committees (HRECs), 266, 267, 268
- human tissue banks, 193
- hydroxychloroquine, 251, 272, 402
- hypertension, 335
- hypotheses, 99, 151–2, 161, 263–4, 300, 301

- hypothesis, 99, 131, 152, 154, 197, 263–5, 300–02, 383, 403, 405
- incidence, 22, 37, 38, 55, 168–9
- incidence rates, 21, 52, 224–5  
  *see also* age-standardised rates;  
  person-time at risk
- incident cases, 37, 38, 40, 200  
  *see also* bathtub analogy
- India, 191–2
- Indigenous Australians, 16, 84–5, 125
- indirect standardisation, 70–2
- individualistic fallacy, 116
- infectious diseases, 11, 37, 43  
  *see also* communicable diseases
- inferences, 298–9
- influencers, 10, 11
- influenza, 10, 48, 133, 145, 146, 147–8, 200  
  in Australia, 8, 51–4, 124–5, 146  
  vaccines, 14, 125  
  World Health Organization and, 147
- information bias, *see* measurement bias
- informed consent, 268
- injection drug use, 305, 339
- Institute of Health Metrics and Evaluation (IHME), 84, 86
- intent to treat analyses, 328
- interaction, 116, 295–7  
  *see also* effect modification
- Interclass Correlation Coefficients, 321
- internal validity, 299, 318, 324–5
- International Classification of Diseases (ICD), 17
- International Clinical Trials Registry Platform, 334
- International Health Regulations, 145
- internet, 11  
  *see also* online surveys; social media; websites
- interval scales, 100–1
- isoniazid, 258–9, 262–3, 357–60
- ivermectin, 251
- Japan, 178
- journals, scientific, *see* scientific journals
- KAP scales, 167
- Kaplan-Meier curves, 359
- Kappa, 321
- Kenya, 190
- kidney (renal) disease, 183, 335
- Lancet, The*, 305
- Lenz, W., 109, 110, 111
- leukaemia, 222
- life expectancy, 55, 72–6, 81, 125, 142, 178
- health-adjusted, 81–6
- life tables, 73–6, 81
- Likert-type scales, 100
- limb defects in babies, 108–12
- Lind, James, 248–9
- lines of best fit, 282–3
- Literary Digest*, 323–4, 326
- liver cancer, 362
- London, 15, 16–17, 115, 130–1, 138, 204
- long COVID-19, 371
- lopinavir–ritonavir, 363
- loss to follow-up, 232, 326–7
- low-income countries, 16, 127, 132, 151, 225, 237, 250
- lung cancer, 95–7, 135–6, 292, 295–7, 364–6, 367
- malaria, 190
- Mantel-Haenszel technique, 236, 341
- maps, 129–30
- matching, 203, 328, 338
- maternal mortality ratio, 132–3
- McBride, William, 110–11
- measles, 305
- measles, mumps and rubella (MMR) vaccine, 305
- measurement, 99–103
- measurement bias, 333  
  *see also* Hawthorne effect;  
  misclassification bias; observer bias; recall bias; self-report bias; social desirability bias
- measures of association, 171–7  
  *see also* prevalence odds ratio (POR); prevalence ratio (PR)
- medical records, 149, 167, 193
- men, 95, 123, 125, 136, 138
- meningococcal disease, 144, 145
- mental health, 16, 161, 167  
  *see also* depression; stress
- mesothelioma, 295
- meta-analyses, 112, 252, 334, 370
- metabolic syndrome, 283–5
- Mexico, 251, 260–1, 350–2
- micro data, 114
- middle-income countries, 132
- migration, 167–8
- misclassification bias, 331–2
- MMR (measles, mumps and rubella) vaccine, 305
- mpox, 377, 410
- monkeypox, 138
- morbidity, 55–6  
  *see also* duration; incidence;  
  prevalence; severity
- mortality, 55, 84  
  *see also* case fatality; life expectancy; mortality rates
- mortality data, 16–17, 143–4
- mortality rate ratio (MRR), 258, 259
- mortality rate, 16, 49, 52, 55, 56
- mpox, 377, 410
- multi-level studies, 116
- multi-organ dysfunction, 223, 227
- multiplicative interaction, 295, 296–7
- multivariate statistical techniques, 341
- muscle-mass, loss of, 251
- narrative reviews, 371
- National Cancer Institute (NCI) (United States), 69, 104, 201
- National Health and Medical Research Council (Australia), 305
- National Health Service (United Kingdom), 222
- National Health Survey (Australia), 139, 167, 177, 183
- National Influenza Centres, 147
- National Institute of Health  
  American Association of Retired Persons (NIH-AARP) Diet and Health Study, 365
- National Notifiable Diseases Surveillance System (NNDSS) (Australia), 144, 145, 146
- National Nutritional Survey (Japan), 178
- National Statement on Ethical Conduct in Human Research (Australia), 266
- National Suicide and Self-Harm Monitoring System (Australia), 149
- Nature*, 357
- New Mexico Elder Health Survey, 355–6
- New Zealand, 139, 177, 334
- nocebo effect, 257, 402
- nominal scales, 99–100
- non-communicable diseases, 127, 133
- non-experimental study designs (observational study designs), 20–2, 103, 106  
  compared with experimental study designs, 104, 106, 247
- examples, 15, 130–1
- inadequate reporting of methods in, 356
- matching of controls in, 328
- STROBE Checklist, 353
- systematic reviews of, 371  
  *see also* analytical study designs;  
  descriptive study designs
- non-maleficence, 106
- non-probability sampling, 163–4
- non-response bias, 326, 328–9
- Nordic countries, 149
- normative values, 77
- notifiable diseases, 144–5
- notifiable diseases surveillance systems, 144–50, 151
- null hypotheses, 263–4, 300–02, 383, 403, 405



- number needed to treat (NNT), 258, 260, 261–3  
 Nuremberg Code, 266  
 nutrition education, 251
- obesity, 16, 124, 285, 335, 339, 362  
 observational study designs, *see* non-experimental study designs (observational study designs)  
 observer bias, 333  
 odds ratio (OR), 21, 193–9, 258, 285  
 older people, 16, 51, 125, 151–2, 355–6, 363  
 online surveys, 164, 328  
 open randomised controlled trials, 250  
 OpenEpi, 302  
 operationalisation, 99  
 ordinal scales, 100  
 Organisation of Economic Cooperation and Development (OECD), 73, 76, 80  
 osteoarthritis, 256  
 osteoporosis, 287  
 Our World in Data platform, 148  
 outbreaks, *see* epidemics  
 outcomes, 4, 98
- p* values, 197, 198, 299–301, 334  
 pandemic fatigue, 14  
 parallel randomised controlled trials, 250  
 passive surveillance systems, 19  
   *see also* notifiable diseases  
   surveillance systems  
 PCR (polymerase chain reaction) tests, 23, 37, 138  
 Pearson's correlation principal component analyses, 321  
 peer review, 12, 334  
 per protocol analysis, 327  
 period life tables, 74–6  
 period prevalence, 38, 168  
 person-time, 49, 221  
 person-time at risk, 224, 225–7  
 personal protective behaviour, 5, 14, 221  
 phocomelia, 108–12  
 pilot studies, 321  
 pipe analogy, 47, 61, 64, 67  
 placebo effect, 257  
 placebos, 22–3, 256–7, 267  
 pneumococcal disease, 145  
 pneumonia, 17  
 point prevalence, 38  
 political perspectives, 18  
 polymerase chain reaction (PCR) tests, 23, 37, 138  
 population attributable proportion, 292  
 population pyramids, 61  
 population size, 37, 47, 61  
 population surveys, 125, 139, 167
- populations, 61, 124, 162, 231  
 ageing of, 140, 225  
 health status of, 123  
 standard, 66  
 stratification of, 51  
 Potential Years of Life Lost (PYLL), 77–80  
 power, 264–5, 302–4  
 precision, 73–4, 298, 301  
 prevalence, 20–1, 55, 283  
   period, 38, 168  
   point, 38  
 prevalence odds ratio (POR), 173–4  
 prevalence proportion, 45–6  
 prevalence ratio (PR), 171, 172, 173–4, 283  
 prevalence surveys, 138–40, 167  
 prevalent cases, 38, 40, 200–1  
   *see also* bathtub analogy  
 primary data, 113–14, 137–9  
 primary disease prevention, 43  
 primary studies, 252, 353  
 PRISMA Statement, 353  
 prisoners, 16, 305  
 probability sampling, 83–139, 140, 63  
 proportions, 45–6, 52, 283  
 prospective cohort studies, 219, 220–1, 223, 236, 237, 238  
   bias in, 232, 233, 234, 237, 327, 331, 364  
   blinding in, 236  
   confounding in, 237–8  
   examples, 220, 221, 234, 350–2, 364–6, 367  
 prospective studies, 326–7, 329  
   *see also* prospective cohort studies; randomised controlled trials (RCTs)  
 protective factors, 165  
 proxy respondents, 193  
 psychometric scales, 167  
 publication bias, 317, 333–4  
 PubMed, 350, 354, 368–9
- quadruple-blind randomised controlled trials, 250  
 qualitative studies, 23, 361, 371  
 quality of life, 81  
 Queensland, 124–5, 145–6, 190  
 questionnaire surveys, 161, 162, 164, 167, 321, 328
- random error, 334  
 random sampling, 83–139, 140, 63  
 randomisation, 248–9, 253–5, 267, 338  
 randomised controlled trials (RCTs), 23–2, 98, 114, 246–70, 362  
   bias in, 327, 328, 329, 331, 333  
   community-based, 251–2  
   CONSORT Statement, 353  
   cost to society of, 270  
   ethical perspectives, 265–8
- examples, 251, 256, 258–9, 260, 262–3, 357–60, 363  
 external validity, 324  
 inadequate reporting of methods in, 356  
 internal validity, 324  
 methodological aspects, 253–65  
 outcome measures, 258–63  
 and relative risk, 288–9  
 RoB 2 tool, 363–4  
 strengths and limitations of, 268–70  
 types, 250
- rapid antigen tests (RATs), 23, 99  
 rates, 9, 46–54  
   adjusted, 51  
   age-specific, 51, 65  
   age-standardised, 66–72, 81, 225  
   annual, 49, 50  
   crude, 51, 64–5  
   incidence, 21, 52, 224–5  
   mortality, 16, 49, 52, 55, 56  
   standardised, 51  
 ratio scales, 101  
 ratios, 45, 51, 72  
 RCTs, *see* randomised controlled trials (RCTs)  
 recall bias, 7, 207–8, 209, 331, 332  
   *see also* self-report bias  
 Receiver Operating Characteristic (ROC) curves, 321–2  
 relationships, context for  
   establishing meaningfulness of, 305  
 relative risk (RR), 21, 224, 227–30, 258, 259, 285, 287, 288–9  
 remission, 41–2, 55–6  
 renal (kidney) disease, 183, 335  
 reporting format for scientific papers, 353  
   abstract, 354  
   discussion and conclusions, 360  
   introduction, 354  
   methods, 354–7  
   results, 357–60  
   title, 353  
 reporting guidelines for study designs, 353, 367  
 representative samples, 83  
 reproducibility, 356–7  
 Reproducibility Project: Cancer Biology, 357  
 research protocols, 114  
 respiratory diseases, 7, 10, 228  
 retrospective cohort studies, 219, 222–4, 237, 238  
   bias in, 232, 233, 234, 236, 238, 328, 331  
   compared with case-control studies, 219  
   examples, 222, 223, 227  
 retrospective studies, *see* case-control studies; retrospective cohort studies  
 rhinoviruses, 99

- risk, 305–7
- risk difference, *see* absolute risk difference
- risk factors, 4
- risk reduction, *see* absolute risk difference
- RoB 2 tool, 363–4
- Robinson, W., 116
- ROC (Receiver Operating Characteristic) curves, 321–2
- Rothman's model of causation, 289–91
- rural locations, 129
- salmonellosis, 144, 145
- sample size, 164, 264, 302–4
- samples, 83, 162, 323
- sampling, 83–139, 140–64, 170
- sampling bias, *see* ascertainment bias
- sanocrysin, 249
- sarcopenia, 355–6
- SARS-CoV-2, 9, 251, 291, 362  
*see also* COVID-19
- Saudi Arabia, 251
- scales of measurement, 99–101
- scatter plots, 141, 282–3
- Science*, 357
- scientific journals, 11–12, 301, 317, 334  
*see also* scientific papers
- scientific literature
  - application of critical thinking to, 349–50
  - see also* scientific journals; scientific papers
- scientific papers
  - application of critical thinking to, 353
  - examples of interpreting, 351–2, 357–60, 364–6, 367
  - reporting format, *see* reporting format for scientific papers
- scientific question, choice of study design and, 361–3
- scientific rigour, 249–8
- scientific studies, 12
- scurvy, 248, 249
- SDGs (Sustainable Development Goals), 16, 125, 132, 141, 150
- search terms, 368–9
- secondary data, 113, 114, 137, 139–44
- secondary disease prevention, 43
- selection bias, 7–8, 164, 204–7, 230–3, 237–8, 323–9  
*see also* allocation bias; ascertainment bias; attrition bias; non-response bias; publication bias; survivor bias; volunteer bias
- self-report bias, 330  
*see also* recall bias
- self-reporting of data, 330, 331, 332, 333
- sensitivity, 321–2
- severity, 22, 55, 86, 87
- sex, 51, 124, 295, 324
- sham surgery, 256–7
- silicosis, 129
- simple randomisation, 254
- single-blind randomised controlled trials, 250
- single-level studies, 115–16
- small gestational age (SGA), 167–8
- smoking, 95–7, 104–5, 124, 135–6, 292, 295–7, 324, 364–6, 367
- Snow, John, 15, 115, 130–1, 289
- social desirability bias, 233, 331, 332
- social determinants of health, 24, 125, 165
- social epidemiology, 124
- social media, 10–11, 164
- source populations, 231
- South Africa, 258–9, 262–3, 357–60
- South Australia, 8, 51–4, 183, 305
- specificity, 321–2
- spiders, white-tail, 207–8
- standard populations, 66
- Standardised Incidence Ratio (SIR), 72
- Standardised Mortality Ratio (SMR), 72
- standardised rates, 51
- statistical significance, 299–302, 304–5
- stratification, 51, 65
- stratified analysis, 341
- stratified randomisation, 254–5, 338
- streptomycin, 249
- stress, 167, 170, 319–20
- STROBE Checklist, 353
- strokes, 85, 123
- study designs, 20–3, 95, 361–3
  - reporting guidelines, 353, 367
  - see also* experimental study designs; non-experimental study designs (observational study designs)
- suicide, 149
- surveillance, disease, *see* disease surveillance
- surveys, *see* online surveys; population surveys; prevalence surveys; questionnaire surveys
- survivor bias, 205, 327, 329  
*see also* attrition bias; healthy worker effect
- Sustainable Development Goals (SDGs), 16, 125, 132, 141, 150
- Sweden, 361
- synergism, 295
- synthesis matrices, 370
- synthesis study designs, *see* burden of disease studies; systematic reviews
- synthesising of evidence, 369–70
- systematic reviews, 9, 10–372  
examples, 9–10, 371
- Taiwan, 234
- target populations, 231
- temporality, 98, 210, 218, 289
- teratogens, 111  
*see also* thalidomide
- tertiary disease prevention, 43
- test–retest processes, 321
- thalidomide, 108–12
- therapeutic misconception, 268  
*see also* volunteer bias
- thromboembolism, 362–3
- time, 35–6, 102
- tobacco, 95–7, 104–5  
*see also* smoking
- triple-blind randomised controlled trials, 250
- tuberculosis (TB), 249–50, 258–9, 262–3, 357–60
- two-by-two tables (contingency tables), 103, 170, 171
- type 1 errors, 264, 265, 302
- type 2 errors, 264–5, 302
- Uganda, 251–2
- umbrella reviews, 371, 372
- United Kingdom
  - British Doctors Study, 95–7, 104
  - cancer in, 222
  - census data in, 140
  - COVID-19 in, 204, 221, 223, 227–8, 362–3
  - limb defects in babies in, 111
  - London, 15, 16–17, 115, 130–1, 138, 204
  - monkeypox in, 138
  - National Health Service, 222
  - vaccination for measles, mumps and rubella in, 305
- United Nations Statistics Division (UNSD), 140
- United States
  - asthma in, 361
  - cardiovascular disease in, 104, 220, 232
  - census data in, 140
  - Centers for Disease Control and Prevention, 145
  - Community Intervention Trial for Smoking Cessation, 104–5
  - COVID-19 in, 151, 170, 221, 251
  - election polling in, 323–4
  - electronic health records in, 149
  - Framingham Heart Study, 104, 220, 232
  - limb defects in babies in, 109
  - liver cancer in, 362
  - lung cancer in, 364–6, 367
  - National Cancer Institute, 69, 104, 201

- National Institute of Health
  - American Association of Retired Persons Diet and Health Study (NIH-AARP), 365
- National Toxicology Program, 363
- New Mexico Elder Health Survey, 355–6
- nutrition education in, 251
- osteoarthritis in, 256
- Public Health Service, 220
- sarcopenia in, 355–6
- tuberculosis in, 249
- units of analysis, 106
- units of observation, 106
- University of Washington Health Science Library, 321
- urban locations, 129
- vaccine hesitancy, 14
- vaccines, 14, 295
  - COVID-19, 5–6, 14, 134, 135
  - influenza, 14, 125
  - measles, mumps and rubella (MMR), 305
- validity, 96, 297–9, 317–22
  - external, 299, 318, 324
  - internal, 299, 318, 324–5
- ventilation, 7, 9–10, 14
- Victoria, 167–8
- viruses, 5–6, 7, 9–10, 14, 99
- vital statistics, 140–1
- vitamin C, 248
- vitamin D, 260–1, 363
- volunteer bias, 269, 326
  - see also* therapeutic misconception
- websites, 11
- white-tail spiders, 207–8
- WHO, *see* World Health Organization (WHO)
- women, 50, 123, 125, 136, 167–8, 303
- workplaces, 319–20, 330
- World Bank, 86, 127
- World Health Organization (WHO), 8, 15–16, 55, 69, 141
  - and COVID-19, 17, 131–2, 145, 148, 150
  - definition of cases by, 199–200
  - Global Cancer Observatory, 149
  - Global Health Estimates, 141, 142, 150, 151, 184
  - and influenza, 147
  - International Clinical Trials Registry Platform, 334
  - population data repositories, 349, 368
  - World Health Statistics, 179
- Wuhan City, China, 17
- Years Lived with Disability (YLD), 86
- Years of Life Lost (YLL), 86
- young adults, 151, 222–3
  - see also* children